Retatrutide (LY3437943) is an investigational triple GLP-1, GIP, and glucagon receptor agonist developed by Eli Lilly, with Phase 2 clinical data published in 2023 showing dose-dependent body weight reductions and HbA1c improvements
Typical requirements include: BMI 40 documented atherosclerotic cardiovascular disease use of a specific Wegovy prior authorization form Key Takeaways Determine whether the patient ever had diabetes Use the correct diagnosis code on the prior authorization Verify whether the insurance plan covers weight-management medications Document baseline weight when starting therapy Consider secondary indications for Medicare coverage Final Thoughts Prior authorizations for GLP-1 medications can be complex and time-consuming
However, there was no observation of cortical bone osteopenia, bone fragility, increased bone resorption, and reduced calcitonin mRNA in the thyroid gland 67
Therefore, optimal titration of the insulin glargine dose was not achieved in most patients
doi: 10.3389/fnbeh.2020.614884
Factors affecting speed include starting weight, diet quality, activity level, sleep, stress, and genetics
